Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.

被引：0

作者：

Gonzalez-Cao, Maria

de las Casas, Clara Mayo

Oramas, Juana

Berciano-Guerrero, Miguel-Angel

De la Cruz, Luis

Cerezuela-Fuentes, Pablo

Arance, Ana Maria

Munoz-Couselo, Eva

Espinosa, Enrique

Puertolas, Teresa

Beveridge, Robert Diaz

Ochenduszko, Sebastian

Silva, Maria Jose Villanueva

Basterretxea, Laura

Bellido, Lorena

Rodriguez-Abreu, Delvys

Drozdowskyj, Ana

Vila, Miguel Angel Molina

Lopez-Martin, Jose Antonio

Berrocal, Alfonso

机构：

[1] Inst Oncol Dr Rosell, Barcelona, Spain

[2] Pangaea Oncol, Barcelona, Spain

[3] Hosp Univ Canarias, Tenerife, Spain

[4] HURyVV Hosp Univ Reg & Virgen Victoria Malaga, Unidad Intercentros Oncol, IBIMA Inst Invest Biomed Malaga, Malaga, Spain

[5] Hosp Univ Virgen Macarena, Seville, Spain

[6] Hosp Virgen Arrixaca, Med Oncol, Murcia, Spain

[7] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[8] Vall dHebron Inst Oncol, Vall dHebron Hosp, Barcelona, Spain

[9] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain

[10] Hosp Miguel Servet, Med Oncol, Zaragoza, Spain

[11] Hosp Univ & Politec La Fe, Valencia, Spain

[12] Hosp Univ Dr Peset, Valencia, Spain

[13] Complexo Hosp Univ Vigo, Vigo, Spain

[14] Hosp Univ Donostia, San Sebastian, Spain

[15] Hosp Univ Salamanca, Salamanca, Spain

[16] Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain

[17] Hosp Univ Dexeus, Inst Oncol Dr Rosell, Dept Oncol, Barcelona, Spain

[18] Hosp 12 Octubre, Madrid, Spain

[19] Hosp Gen Univ Valencia, Valencia, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9528

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9528

引用

页数：3

共 50 条

[1] Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan
Omid Hamid
Rene Gonzalez
Jeffrey R. Infante
Manish R. Patel
F. Stephen Hodi
Karl D. Lewis
Hussein A. Tawbi
Genevive Hernandez
Matthew J. Wongchenko
YiMeng Chang
Louise Roberts
Marcus Ballinger
Yibing Yan
Edward Cha
Patrick Hwu
Nature Medicine, 2019, 25 : 929 - 935
[2] Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Sullivan, Ryan J.
Hamid, Omid
Gonzalez, Rene
Infante, Jeffrey R.
Patel, Manish R.
Hodi, F. Stephen
Lewis, Karl D.
Tawbi, Hussein A.
Hernandez, Genevive
Wongchenko, Matthew J.
Chang, YiMeng
Roberts, Louise
Ballinger, Marcus
Yan, Yibing
Cha, Edward
Hwu, Patrick
NATURE MEDICINE, 2019, 25 (06) : 929 - +
[3] A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
Lopez-Martin, Jose A.
Berrocal, Alfonso
Gonzalez-Cao, Maria
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P. Algazi
Megan Othus
Adil I. Daud
Roger S. Lo
Janice M. Mehnert
Thach-Giao Truong
Robert Conry
Kari Kendra
Gary C. Doolittle
Joseph I. Clark
Michael J. Messino
Dennis F. Moore
Christopher Lao
Bryan A. Faller
Rangaswamy Govindarajan
Amy Harker-Murray
Luke Dreisbach
James Moon
Kenneth F. Grossmann
Antoni Ribas
Nature Medicine, 2020, 26 : 1564 - 1568
[5] Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Maria Gonzalez-Cao
Clara Mayo de las Casas
Juana Oramas
Miguel A. Berciano-Guerrero
Luis de la Cruz
Pablo Cerezuela
Ana Arance
Eva Muñoz-Couselo
Enrique Espinosa
Teresa Puertolas
Roberto Diaz Beveridge
Sebastian Ochenduszko
Maria-Jose Villanueva
Laura Basterretxea
Lorena Bellido
Delvys Rodriguez
Begoña Campos
Clara Montagut
Ana Drozdowskyj
Miguel A. Molina
Jose Antonio Lopez-Martin
Alfonso Berrocal
Nature Communications, 12
[6] Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Gonzalez-Cao, Maria
Mayo Casas, Clara
Oramas, Juana
Berciano-Guerrero, Miguel A.
de la Cruz, Luis
Cerezuela, Pablo
Arance, Ana
Munoz-Couselo, Eva
Espinosa, Enrique
Puertolas, Teresa
Diaz Beveridge, Roberto
Ochenduszko, Sebastian
Villanueva, Maria-Jose
Basterretxea, Laura
Bellido, Lorena
Rodriguez, Delvys
Campos, Begona
Montagut, Clara
Drozdowskyj, Ana
Molina, Miguel A.
Antonio Lopez-Martin, Jose
Berrocal, Alfonso
NATURE COMMUNICATIONS, 2021, 12 (01)
[7] Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.
Larkin, James M. G.
Yan, Yibing
McArthur, Grant A.
Ascierto, Paolo Antonio
Liszkay, Gabriella
Maio, Michele
Mandala, Mario
Demidov, Lev V.
Stroyakovskiy, Daniil
Thomas, Luc
De La Cruz-Merino, Luis
Atkinson, Victoria
Dutriaux, Caroline
Garbe, Claus
Wongchenko, Matthew
Rooney, Isabelle Anne
Chang, Ilsung
Hack, Stephen Paul
Dreno, Brigitte
Ribas, Antoni
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Treatment beyond progression in advanced BRAF-mutated melanoma with vemurafenib and cobimetinib: Results from the BRIM7 trial
Lewis, K.
Ribas, A.
Gonzalez, R.
Hamid, O.
Daud, A.
Puzanov, I.
Hsu, J.
Choong, N.
Koralek, D.
McArthur, G.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S679 - S679
[9] Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).
Larkin, James M. G.
McArthur, Grant A.
Ribas, Antoni
Ascierto, Paolo Antonio
Gallo, Jorge D.
Rooney, Isabelle Anne
Chang, Ilsung
Dreno, Brigitte
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.
Shaikh, Saba
Zang, Yan
Hanmer, Janel
Wang, Hong
Lin, Yan
Davar, Diwakar
Zarour, Hassane M.
Kirkwood, John M.
Najjar, Yana G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →